Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aclaris Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ACRS
Nasdaq
8731
https://www.aclaristx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aclaris Therapeutics Inc
Aclaris Therapeutics Provides 2023 Outlook
- Jan 6th, 2023 12:01 pm
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China
- Nov 29th, 2022 12:00 pm
Lab Notes: Biotech firm bioMerieux unveils new product for detecting spoiled wine
- Nov 26th, 2022 6:39 pm
Aclaris Therapeutics Announces Key Leadership Transitions
- Nov 22nd, 2022 9:01 pm
Aclaris Therapeutics Looks Promising on the Charts
- Nov 16th, 2022 5:10 pm
Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences
- Nov 10th, 2022 9:01 pm
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
- Nov 8th, 2022 1:25 pm
Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
- Nov 8th, 2022 12:00 pm
We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
- Oct 26th, 2022 10:44 am
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
- Sep 27th, 2022 11:00 am
Aclaris Therapeutics (NASDAQ:ACRS) pulls back 7.4% this week, but still delivers shareholders massive 110% CAGR over 3 years
- Sep 15th, 2022 10:46 am
Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- Aug 30th, 2022 11:00 am
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
- Aug 25th, 2022 11:00 am
Health Check: How Prudently Does Aclaris Therapeutics (NASDAQ:ACRS) Use Debt?
- Aug 5th, 2022 11:59 am
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates
- Aug 3rd, 2022 12:25 pm
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
- Aug 3rd, 2022 11:00 am
Aclaris Therapeutics Expands Leadership Team
- Aug 1st, 2022 11:00 am
Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to Buy
- Jul 15th, 2022 4:00 pm
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
- Jul 8th, 2022 1:40 pm
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
- Jun 22nd, 2022 1:40 pm
Scroll